Genetic mutations in apolipoprotein L1 (ApoL1) are associated with kidney disease. Apolipoprotein L1 mutations are common in African Americans (∼39% and 12% have 1 and 2 high-risk alleles, respectively). Carrying 2 ApoL1 risk alleles may explain much of the excess rate of kidney failure in African Americans compared to European Americans. Apolipoprotein L1 also has implications for kidney transplantation. Kidney grafts from deceased donors with 2 ApoL1 risk alleles have worse graft survival, but outcomes appear unaffected by recipient ApoL1 status. Unknown is whether donation increases the risk of kidney failure in living donors with 2 ApoL1 risk alleles and whether their donated kidneys have worse graft survival. There are 4 options to consider: (1) remain silent about ApoL1 risk alleles and renal failure and wait for more data; (2) counsel about race, ApoL1, and subsequent renal failure abstractly but remain agnostic about donor testing until more data are available; (3) provide counseling and encourage genotyping of prospective living donors of African ancestry as part of the living donor workup; or (4) mandate testing of all prospective living donors. We support option 3, and recommend, with donor permission, to discuss the results with potential recipients to promote informed decision-making. We also argue for a voluntary donor registry that collects long-term follow-up information. We provide ethical arguments to support these recommendations.
HsuCYLinFVittinghoffEShlipakMG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol. 2003;14(11):2902–2907.
2.
ChoiAIRodriguezRABacchettiPBertenthalDHernandezGTO’HareAM. White/black racial differences in risk of end-stage renal disease and death. Am J Med. 2009;122(7):672–678. doi:10.1016/amjmed.2008.11.021.
3.
FosterMCCoreshJFornageM. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol. 2013;24(9):1484–1491. doi:10.1681/ASN.2013010113.
4.
PalanisamyAReeves-DanielAMFreedmanBI. The impact of APOL1, CAV1, and ABCB1 gene variants on outcomes in kidney transplantation: donor and recipient effects. Pediatr Nephrol. 2014;29(9):1485–1492. doi:10.1007/s00467-013-2531-7.
5.
ParsaAKaoWHXieD. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med. 2013;369(23):2183–2196. doi: 10.1056/NEJMoa1310345.
6.
GenoveseGFriedmanDJRossMD. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–845. doi:10.1126/science.1193032.
7.
Reeves-DanielAMDePalmaJABleyerAJ. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant. 2011;11(5):1025–1030. doi:10.1111/j.1600-6143.2011.03513.x.
8.
FreedmanBIJulianBAPastanSO. Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure. Am J Transplant. 2015;15(6):1615–1622. doi:10.1111/ajt.13223.
9.
LeeBTKumarVWilliamsTA. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant. 2012;12(7):1924–1928. doi:10.1111/j.1600-6143.2012.04033.x.
10.
MadhavanSMO’TooleJF. The biology of APOL1 with insights into the association between APOL1 variants and chronic kidney disease. Clin Exp Nephrol. 2014;18(2):238–242.
11.
QuagginSEGeorgeALJr. Apolipoprotein l1 and the genetic basis for racial disparity in chronic kidney disease. J Am Soc Nephrol. 2011;22(11):1955–1958. doi:10.1681/ASN.2011090932.
LanXJhaveriAChengK. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol. 2014;307(3):f326–f336. doi:10.1152/ajprenal.00647.2013.
14.
FreedmanBI. APOL1 and nephropathy progression in populations of African ancestry. Semin Nephrol. 2013;33(5):425–432. doi:10.1016/j.semnephrol.2013.07.004.
15.
MjøenGHallanSHartmannA. Long-term risks for kidney donors. Kidney Int. 2014;86(1):162–167. doi:10.1038/ki.2013.460.
16.
MuzaaleADMassieABWangMC. Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311(6):579–586. doi:10.1001/jama.2013.285141.
17.
OjoAKnollGA. APOL1 genotyping of African American deceased organ donors: not just yet. Am J Transplant. 2015;15(6):1457–1458. doi:10.1111/ajt.13230.
18.
FreedmanBIJulianBA. Should kidney donors be genotyped for APOL1 risk alleles?Kidney Int. 2015;87(4):671–673. doi:10.1038/ki.2015.16.
19.
CohenDMMittalhenkleAScottDLYoungCJNormanDJ. African American living-kidney donors should be screened for APOL1 risk alleles. Transplantation. 2011;92(7):722–725. doi:10.1097/TP.0b013e31822eec39.
20.
RiellaLVSheridanAM. Testing for high-risk APOL1 alleles in potential living kidney donors. Am J Kidney Dis. 2015;66(3):396–401. doi:10.1053/j.ajkd.2015.04.046.
21.
SearsDA. The morbidity of sickle cell trait: a review of the literature. Am J Med. 1978;64(6):1021–1036.
22.
JohnsonLN. Sickle cell trait: an update. J Natl Med Assoc. 1982;74(8):751–757.
23.
NaikRPDerebailVKGramsME. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014;312(20):2115–2125. doi:10.1001/jama.2014.15063.
24.
ReesePPHooACMageeCC. Screening for sickle trait among potential live kidney donors: policies and practices in US transplant centers. Transpl Int. 2008;21(4):328–331.
25.
FreedmanBIMureaM. Target organ damage in African American hypertension: role of APOL1. Curr Hypertens Rep. 2012;14(1):21–28. doi:10.1007/s11906-0237-4.
26.
MischelMH. Uncertainty in illness. Image J Nurs Sch. 1988;20(4):225–232.
27.
HanPKKleinWMPAroraNK. Varieties of uncertainty in health care: a conceptual taxonomy. Med Decis Making. 2011;31(6):828–838. doi:10.1177/0272989X11393976.
EddyDM. Variations in physician practice: the role of uncertainty. Health Aff. 1984;3(2):74–89.
30.
FraserFC. Genetic counselling. Am J Hum Genet. 1974;26(5):636–661.
31.
ChiengWSChanNLeeSC. Non-directive genetic counselling—respect for autonomy or unprofessional practice?Ann Acad Med Singapore. 2011;40(1):36–42.
32.
WeilJ. Psychosocial genetic counseling in the post-nondirective era: a point of view. J Genet Couns. 2003;12(3):199–211.
33.
MackenzieCStoljarN. Introduction: autonomy reconfigured. In: MackenzieCStoljarN. eds. Relational Autonomy: Feminist Perspectives on Autonomy, Agency and the Social Self. New York, NY: Oxford University Press; 2000:3–31.
34.
ElwynGFroschDThomsonR. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367.
35.
WalterJKRossLF. Relational autonomy: moving beyond the limits of isolated individualism. Pediatrics. 2014;133(suppl 1):s16–s23. doi:10.1542/peds.2013.3608D.
36.
ItoKBickAGFlannickJ. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res. 2014;114(5):845–850. doi:10.1161/CIRCRESAHA.114.302347.
37.
Organ Procurement and Transplantation Network Policies. Web site. http://sa.gov/media/1200/optn_policies.pdf. See, policy 15.3 Informed Consent of Transmissible Disease Risk; and for HIV specifically, see policy 2.7 HIV Screening of Potential Deceased Donors or Table 14.4E: Living Donor Exclusion Criteria. Accessed 2016.
38.
HidalgoGTejaniCClaytonR. Factors limiting the rate of living-related kidney donation to children in an inner city setting. Pediatr Transplant. 2001;5(6):419–424.
Genetic Information Nondiscrimination Act of 2008, H.R. 493, 110th Congress.
42.
GeppertCMRobertsLW. Ethical issues in the use of genetic information in the workplace: a review of recent developments. Curr Opin Psychiatry. 2005;18(5):518–524.
43.
ParkmanAAFolandJAndersonB. Public awareness of genetic nondiscrimination laws in four states and perceived importance of life insurance protections. J Genet Couns. 2015;24(3):512–521. doi:10.1007/s10897-014-9771-y.
44.
GreenRCLautenbachDMcGuireAL. GINA, genetic discrimination, and genomic medicine. N Engl J Med. 2015;372(5):397–399. doi:10.1056/NEJMp140477643.
